Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Beta Bionics, Inc. (BBNX : NSDQ)
 
 • Company Description   
Beta Bionics Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of solutions. Beta Bionics Inc. is based in IRVINE, Calif.

Number of Employees: 420

 
 • Price / Volume Information   
Yesterday's Closing Price: $12.63 Daily Weekly Monthly
20 Day Moving Average: 1,175,330 shares
Shares Outstanding: 44.38 (millions)
Market Capitalization: $560.55 (millions)
Beta: 5.59
52 Week High: $32.71
52 Week Low: $8.89
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -8.68% -7.88%
12 Week -57.01% -57.06%
Year To Date -58.55% -58.75%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11 HUGHES
-
IRVINE,CA 92618
USA
ph: 949-427-7785
fax: -
ir@betabionics.com http://www.betabionics.com
 
 • General Corporate Information   
Officers
Sean Saint - Chief Executive Officer and Director
Adam Lezack - Chairperson of the Board of Directors
Stephen Feider - Chief Financial Officer
Sean Carney - Director
Dan Dearen - Director

Peer Information
Beta Bionics, Inc. (ABMD)
Beta Bionics, Inc. (DMDS)
Beta Bionics, Inc. (CPWY.)
Beta Bionics, Inc. (EQUR)
Beta Bionics, Inc. (ECIA)
Beta Bionics, Inc. (FMS)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 08659B102
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/25
Next Expected EPS Date: 05/05/26
Share - Related Items
Shares Outstanding: 44.38
Most Recent Split Date: (:1)
Beta: 5.59
Market Capitalization: $560.55 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.53 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.96 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/05/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.93
Price/Cash Flow: -
Price / Sales: 5.59
EPS Growth
vs. Year Ago Period: 83.52%
vs. Previous Quarter: 9.09%
Sales Growth
vs. Year Ago Period: 57.15%
vs. Previous Quarter: 17.86%
ROE
12/31/25 - -20.29
09/30/25 - -35.72
06/30/25 - -59.34
ROA
12/31/25 - -18.32
09/30/25 - -20.69
06/30/25 - -26.86
Current Ratio
12/31/25 - 8.66
09/30/25 - 10.64
06/30/25 - 14.68
Quick Ratio
12/31/25 - 7.96
09/30/25 - 9.83
06/30/25 - 13.79
Operating Margin
12/31/25 - -60.60
09/30/25 - -67.03
06/30/25 - -70.36
Net Margin
12/31/25 - -73.02
09/30/25 - -87.89
06/30/25 - -94.04
Pre-Tax Margin
12/31/25 - -73.02
09/30/25 - -87.89
06/30/25 - -94.04
Book Value
12/31/25 - 6.53
09/30/25 - 6.70
06/30/25 - 6.94
Inventory Turnover
12/31/25 - 2.38
09/30/25 - 2.41
06/30/25 - 3.10
Debt-to-Equity
12/31/25 - 0.00
09/30/25 - 0.00
06/30/25 - 0.00
Debt-to-Capital
12/31/25 - 0.00
09/30/25 - 0.00
06/30/25 - 0.00
 

Powered by Zacks Investment Research ©